Description

1. Product Description 

XMP-629 (CAS 316805-65-9), also known as XOMA-629, is a synthetic cationic ?-helical peptide designed to target microbial pathogens and endotoxins through a combination of direct antimicrobial activity and immunomodulatory effects. The peptide’s ?-helical structure enables membrane disruption, while its cationic nature facilitates binding to negatively charged bacterial membranes and endotoxins.

Background

Bacterial infections remain a global health challenge, with increasing antimicrobial resistance among key pathogens. XMP-629 represents a novel class of peptide-based antimicrobials that act both by direct bacterial killing and modulating host immune responses, reducing inflammatory damage caused by endotoxins such as lipopolysaccharides (LPS).

Scientific Relevance

• Broad-Spectrum Antimicrobial Research: Effective against Gram-positive bacteria (S. aureus, S. pyogenes) and Gram-variable bacteria (P. acnes).

• Endotoxin Inhibition: Neutralizes bacterial LPS, preventing overactivation of host immune responses.

• Immunomodulatory Studies: Supports investigation of host-pathogen interactions and innate immunity modulation.

• Preclinical Therapeutic Modeling: Provides a platform for developing peptide-based anti-infective therapeutics.

Advantages in Research

• Dual action: direct antimicrobial + immunomodulatory effects.

• High potency against multiple clinically relevant pathogens.

• GMP-grade production ensures reproducible results.

• Suitable for in vitro cell-based assays, ex vivo tissue studies, and in vivo infection models.

2. Product Specifications 

3. Mechanism of Action & Research Applications 

Mechanism of Action

XMP-629 exerts its biological activity through a dual-mode mechanism:

1. Direct Antimicrobial Activity

   • The cationic ?-helical structure allows electrostatic interactions with negatively charged bacterial membranes.

   • Disruption of lipid bilayers leads to membrane permeabilization and bacterial cell death.

   • Effective against Propionibacterium acnes, Staphylococcus aureus, and Streptococcus pyogenes.

2. Endotoxin Inhibition

   • Binds lipopolysaccharide (LPS) molecules from Gram-negative bacterial walls.

   • Neutralizes endotoxin activity, preventing excessive pro-inflammatory cytokine release.

3. Immunomodulation

   • Modulates innate immune signaling pathways.

   • Enhances host defenses while reducing tissue-damaging inflammation.

Research Applications

1. Microbiology Studies

   • In vitro bacterial killing assays.

   • Mechanistic studies of membrane disruption by cationic peptides.

2. Infectious Disease Models

   • Preclinical in vivo studies for skin infections, systemic infections, and sepsis.

3. Immunology Research

   • Investigation of endotoxin-neutralizing effects.

   • Modulation of cytokine profiles in macrophage and dendritic cell cultures.

4. Translational Research

   • Potential development of peptide-based therapeutics for antibiotic-resistant infections.

   • Studies on host-pathogen interaction modulation.

5. Comparative Peptide Studies

   • Benchmarking against other antimicrobial peptides and antibiotics for efficacy, spectrum, and immunomodulatory potential.

     

4. Side Effects (Research Reference) 

In preclinical and laboratory studies, XMP-629 has demonstrated:

• Species-specific cytotoxicity: Low toxicity in mammalian cell cultures at effective antimicrobial doses.

• Immune modulation effects: Reduction in pro-inflammatory cytokines may alter experimental immune responses.

• Dose-dependent effects: High concentrations may affect membrane integrity in non-target cells.

• Stability considerations: Activity maintained in lyophilized form; avoid repeated freeze-thaw cycles.

 Observations are strictly for research reference only. XMP-629 is not intended for human or veterinary use.

5. Disclaimer

For laboratory research use only. Not for human or veterinary use.

6. Keywords

• XMP-629

• XMP-629 CAS 316805-65-9

• XOMA-629 peptide

• Cationic ?-helical antimicrobial peptide

• Endotoxin inhibitor peptide

• Broad-spectrum antimicrobial research peptide

• Propionibacterium acnes inhibitor peptide

• Staphylococcus aureus research peptide

• Streptococcus pyogenes antimicrobial peptide

• GMP supplier XMP-629